Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pharmacodynamics of teicoplanin against MRSA.

Ramos-Martín V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, Pea F, Neely MN, Hope WW.

J Antimicrob Chemother. 2017 Dec 1;72(12):3382-3389. doi: 10.1093/jac/dkx289.

PMID:
28962026
2.

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.

Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid V, Elens L.

Front Pharmacol. 2017 Jun 8;8:358. doi: 10.3389/fphar.2017.00358. eCollection 2017.

3.

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.

Ramos-Martín V, Neely MN, McGowan P, Siner S, Padmore K, Peak M, Beresford MW, Turner MA, Paulus S, Hope WW.

J Antimicrob Chemother. 2016 Nov;71(11):3168-3178. Epub 2016 Aug 19.

4.

A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.

Mathew SK, Mathew BS, Neely MN, Naik GS, Prabha R, Jacob GG, K S, Fleming DH.

Ther Drug Monit. 2016 Oct;38(5):593-9. doi: 10.1097/FTD.0000000000000323.

PMID:
27454665
5.

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51. doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

6.

Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, Schumitzky A, Bleyzac N, Goutelle S.

Ther Drug Monit. 2016 Jun;38(3):332-42. doi: 10.1097/FTD.0000000000000276.

7.

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH.

J Infect Chemother. 2016 Feb;22(2):78-83. doi: 10.1016/j.jiac.2015.10.009. Epub 2015 Dec 17.

PMID:
26712584
8.

Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?

Billat PA, Woillard JB, Essig M, Sauvage FL, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F.

J Antimicrob Chemother. 2016 Feb;71(2):484-9. doi: 10.1093/jac/dkv342. Epub 2015 Nov 3.

PMID:
26538506
9.

Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.

Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH.

J Antimicrob Chemother. 2015 Jul;70(7):2068-73. doi: 10.1093/jac/dkv067. Epub 2015 Mar 22.

PMID:
25802286
10.

A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.

Neely M, Kaplan EL, Blumer JL, Faix DJ, Broderick MP.

Antimicrob Agents Chemother. 2014 Nov;58(11):6735-41. doi: 10.1128/AAC.02744-14. Epub 2014 Sep 2.

11.

Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.

Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, Marquet P, Saint-Marcoux F.

Br J Clin Pharmacol. 2014 Oct;78(4):836-46. doi: 10.1111/bcp.12394.

12.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

13.

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.

Åsberg A, Bjerre A, Neely M.

Pediatr Transplant. 2014 Feb;18(1):103-11. doi: 10.1111/petr.12179. Epub 2013 Oct 23.

14.

Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH.

Antimicrob Agents Chemother. 2013 Dec;57(12):5854-9. doi: 10.1128/AAC.00474-13. Epub 2013 Sep 9.

15.

Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A.

J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):189-99. doi: 10.1007/s10928-013-9302-8. Epub 2013 Feb 13.

16.

Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.

Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, Kiss A, Neely M.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb;115(2):224-32. doi: 10.1016/j.oooo.2012.08.455. Epub 2012 Dec 12.

17.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW.

Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.

Supplemental Content

Loading ...
Support Center